Consistent with our data, recent studies have shown that TRAIL-resistant cells were sensitized by combinatorial treatment of TRAIL with cetuximab (an anti-EGFR monoclonal antibody) or sorafenib (a multi-kinase inhibitor that acts on Raf kinases, MEK, and ERK signaling) in different cancer cell lines and tumor xenograft models [39, 40]. Here, MAP2K7 is linked to cancer.